Gracell Biotechnologies Net Income

As of the most recent data (September 2023), GRCL shows a net income of $-500M. That compares with $-600M in the prior-year period — up 17.4% year over year. That is below the Healthcare sector average of $16B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GRCL's net income is now $-500M (was $-600M) — a 17.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Gracell Biotechnologies is outperforming or lagging.

The Healthcare sector average net income is about $16B. Gracell Biotechnologies is at $-500M, which is lower that average. That is roughly 103.0% below the sector mean. Use the comparison chart on this page to see how GRCL stacks up against individual peers as well.

Tracking GRCL's net income over time shows whether Gracell Biotechnologies is scaling, shrinking, or reshaping that part of the business. The current reading is $-500M That compares with $-600M in the prior-year period — up 17.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net income page, Stockcircle has Gracell Biotechnologies's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net income (currently $-500M) with ownership activity and broader fundamentals.